These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 8347251)

  • 21. HLA antigens on leukocyte fragments and plasma proteins: prestorage leukoreduction by filtration.
    Dzik S; Szuflad P; Eaves S
    Vox Sang; 1994; 66(2):104-11. PubMed ID: 8184591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components--a randomized trial.
    Oksanen K; Kekomäki R; Ruutu T; Koskimies S; Myllylä G
    Transfusion; 1991 Sep; 31(7):588-94. PubMed ID: 1891788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HLA alloimmunization with leukocyte concentrates from HLA-matched and HLA-non-matched donors in patients with Hunter's syndrome.
    Kakaiya RM; Greenstein R; Pisciotto P; Slocum SK; Rosen D; Cable RG; Morse EE; Gainey A
    Ann Clin Lab Sci; 1985; 15(5):435-40. PubMed ID: 3933403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Refractory thrombocytopenia by HLA alloimmunization in a multitransfused patient].
    Kaeffer N; Papion H; Menguy E; Peillon C; Bastit D
    Ann Fr Anesth Reanim; 1993; 12(1):60-3. PubMed ID: 8338266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bedside filtration of blood products in the prevention of HLA alloimmunization--a prospective randomized study. Alloimmunisation Study Group.
    Williamson LM; Wimperis JZ; Williamson P; Copplestone JA; Gooi HC; Morgenstern GR; Norfolk DR
    Blood; 1994 May; 83(10):3028-35. PubMed ID: 8180400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of HLA alloimmunization by using leukocyte-depleted components.
    Andreu G; Dewailly J
    Curr Stud Hematol Blood Transfus; 1994; (60):29-40. PubMed ID: 8088168
    [No Abstract]   [Full Text] [Related]  

  • 27. Filtration of platelet concentrates.
    Müller N
    Infusionstherapie; 1991 Jun; 18 Suppl 1():19-23. PubMed ID: 1917059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HPA antibodies in Algerian multitransfused patients: Prevalence and involvement in platelet refractoriness.
    Brouk H; Bertrand G; Zitouni S; Djenouni A; Martageix C; Griffi F; Kaplan C; Ouelaa H
    Transfus Apher Sci; 2015 Jun; 52(3):295-9. PubMed ID: 25620758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platelet transfusions: the problem of refractoriness.
    Murphy MF; Waters AH
    Blood Rev; 1990 Mar; 4(1):16-24. PubMed ID: 2182145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequency and causes of refractoriness in multiply transfused patients.
    Legler TJ; Fischer I; Dittmann J; Simson G; Lynen R; Humpe A; Riggert J; Schleyer E; Kern W; Hiddemann W; Köhler M
    Ann Hematol; 1997 Apr; 74(4):185-9. PubMed ID: 9174547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
    Amemiya Y
    Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of leukocyte-reduced blood components.
    Miller JP; Mintz PD
    Hematol Oncol Clin North Am; 1995 Feb; 9(1):69-90. PubMed ID: 7737945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children].
    Pereira J; Bronfman L; Bertín P; Marzouka E; Hidalgo P; Amaya S; Mezzano D
    Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sensitization by platelet transfusion.
    Brand A
    Schweiz Med Wochenschr; 1991 Mar; 121(13):467-9. PubMed ID: 2031162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alloimmunization as a problem for platelet transfusion.
    Bonacossa IA
    Transfus Med Rev; 1990 Apr; 4(2):144-8. PubMed ID: 2134622
    [No Abstract]   [Full Text] [Related]  

  • 36. Prevention of primary HLA class I allo-immunization with leucocyte-poor blood components produced without the use of platelet filters.
    Ten Haaft MA; Van den Berg-Loonen PM; Van Rhenen DJ
    Vox Sang; 1992; 63(4):257-61. PubMed ID: 1481473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Filtration of buffy coat free red cell concentrates in additive solution.
    Dietrich G; Dietrich K; Kretschmer V; Eckle R
    Infusionsther Transfusionsmed; 1992 Jun; 19(3):151-6. PubMed ID: 1498559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of HLA- and HPA--matched platelets in alloimmunized patients.
    Kekomäki R
    Vox Sang; 1998; 74 Suppl 2():359-63. PubMed ID: 9704468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human leukocyte antigen alloimmunization prevention mechanisms in blood transfusion.
    Adane T; Enawgaw B
    Asian J Transfus Sci; 2023; 17(2):264-272. PubMed ID: 38274979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics and natural history of alloimmunization following HLA-matched leukocyte transfusion in Hunter's syndrome.
    Kakaiya RK; Greenstein R; Pisciotto PT; Slocum SK; Rosen D; Cable RG; Morse EE
    Ann Clin Lab Sci; 1984; 14(4):276-84. PubMed ID: 6431893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.